WO2006083906A3 - Compositions containing the anti-angiogenic phscn-peptide - Google Patents

Compositions containing the anti-angiogenic phscn-peptide Download PDF

Info

Publication number
WO2006083906A3
WO2006083906A3 PCT/US2006/003461 US2006003461W WO2006083906A3 WO 2006083906 A3 WO2006083906 A3 WO 2006083906A3 US 2006003461 W US2006003461 W US 2006003461W WO 2006083906 A3 WO2006083906 A3 WO 2006083906A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
formulation
phscn
cys
angiogenic
Prior art date
Application number
PCT/US2006/003461
Other languages
French (fr)
Other versions
WO2006083906A2 (en
Inventor
Andrew P Mazar
Hashem Heiati
Jay Schrier
Ming Li
Scott Harris
Original Assignee
Attenuon Llc
Andrew P Mazar
Hashem Heiati
Jay Schrier
Ming Li
Scott Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc, Andrew P Mazar, Hashem Heiati, Jay Schrier, Ming Li, Scott Harris filed Critical Attenuon Llc
Priority to EP06720021A priority Critical patent/EP1843779A2/en
Priority to CA002596255A priority patent/CA2596255A1/en
Priority to JP2007553365A priority patent/JP2008528630A/en
Priority to AU2006210895A priority patent/AU2006210895A1/en
Publication of WO2006083906A2 publication Critical patent/WO2006083906A2/en
Publication of WO2006083906A3 publication Critical patent/WO2006083906A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein are compositions/formulations of the Cys-containing anti-angiogenic peptide Pro-His-Ser-Cys-Asn (preferably in its capped form as Ac-PHSCN-NH2) or acid addition salts thereof or analogue thereof, that comprise at least one additional compound that stabilizes the peptide or analogue against spontaneous tandem dimerization or higher oligomerization. Preferred formulations include an acidic buffer such as citrate, glycine as an excipient and bulking agent. Optional additional components of the formulation are a reducing agent, a non-thiol biocompatible anti-oxidant, a lyoprotectant (typically one or more sugars, one or more amino acids, one or more methylamine, one or more lyotropic salts, and/or one or more polyols. Also provided is an article of manufacture or kit comprising the formulation in solution or in lyophilized form. A method of inhibiting angiogenesis in a subject, comprising administering to the subject the peptide in the above formulation is also disclosed.
PCT/US2006/003461 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic phscn-peptide WO2006083906A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06720021A EP1843779A2 (en) 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic phscn-peptide
CA002596255A CA2596255A1 (en) 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic phscn-peptide
JP2007553365A JP2008528630A (en) 2005-02-01 2006-02-01 Composition comprising anti-angiogenic PHSCN peptide
AU2006210895A AU2006210895A1 (en) 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic PHSCN-peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64839105P 2005-02-01 2005-02-01
US60/648,391 2005-02-01

Publications (2)

Publication Number Publication Date
WO2006083906A2 WO2006083906A2 (en) 2006-08-10
WO2006083906A3 true WO2006083906A3 (en) 2006-10-05

Family

ID=36581633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/003461 WO2006083906A2 (en) 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic phscn-peptide

Country Status (6)

Country Link
EP (1) EP1843779A2 (en)
JP (1) JP2008528630A (en)
KR (1) KR20070100832A (en)
AU (1) AU2006210895A1 (en)
CA (1) CA2596255A1 (en)
WO (1) WO2006083906A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2083856T1 (en) 2007-08-15 2011-02-28 Circassia Ltd Peptides for desensibilization against allergens
CN101503458B (en) * 2008-02-04 2012-05-09 上海市第一人民医院 Small molecule polypeptide for preventing and treating angiogenesis and use thereof
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011066386A1 (en) * 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
JP6475714B2 (en) * 2013-11-07 2019-02-27 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル Storage stable freeze-dried tripeptide formulation
KR20210045397A (en) * 2018-07-11 2021-04-26 이뮤니티 파르마 엘티디. Peptide compounds and therapeutic uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
WO1998022617A1 (en) * 1996-11-21 1998-05-28 The Regents Of The University Of Michigan Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer
US20040162239A1 (en) * 2002-11-25 2004-08-19 Allan Amy L. Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
WO1998022617A1 (en) * 1996-11-21 1998-05-28 The Regents Of The University Of Michigan Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer
US20040162239A1 (en) * 2002-11-25 2004-08-19 Allan Amy L. Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIVANT D L ET AL: "ANTI-INVASIVE, ANTITUMORIGENIC, AND ANTIMETASTATIC ACTIVITIES OF THE PHSCN SEQUENCE IN PROSTATE CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 309 - 320, XP001147065, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2006210895A1 (en) 2006-08-10
CA2596255A1 (en) 2006-08-10
EP1843779A2 (en) 2007-10-17
KR20070100832A (en) 2007-10-11
JP2008528630A (en) 2008-07-31
WO2006083906A2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2006083906A3 (en) Compositions containing the anti-angiogenic phscn-peptide
WO2010146598A3 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
ECSP045496A (en) "INSULIN ACID PREPARATIONS WITH IMPROVED STABILITY"
WO2009039972A3 (en) Use of muramyl dipeptide (mdp) as a therapeutic agent
WO2010030670A3 (en) Compositions and methods for the prevention of oxidative degradation of proteins
CA2102693A1 (en) Protein formulation comprising growth hormone
WO2009046863A3 (en) Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent
NZ593145A (en) Compositions with reduced dimer formation
WO2008089491A3 (en) Modifications of peptide compositions to increase stability and delivery efficiency
WO2005009370A3 (en) Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
WO2009039971A3 (en) Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
WO2009043526A3 (en) Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent
AR043863A1 (en) COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM, USEFUL FOR INJECTION
WO2009033760A3 (en) Use of fibronectin fragment (196-203 ) as a therapeutic agent
WO2009033738A3 (en) Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
WO2009040050A3 (en) Use of calcitonin as anti-angiogenic agent
WO2011039444A3 (en) Composition, use, and preservation method
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
WO2007092343A3 (en) Novel epoprostenol formulation and method of making thereof
WO2004062646A9 (en) Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
WO2009033761A3 (en) Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent
EP2168442A3 (en) Geranylamine derivatives of oxalic acid
CA2558985A1 (en) Erythropoietin liquid formulation
WO2009130181A3 (en) Dry transglutaminase composition
WO2009108713A3 (en) Topical compositions and methods utilizing peptides containing lipid-modified cysteine-containing peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2596255

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007553365

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006210895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006720021

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006210895

Country of ref document: AU

Date of ref document: 20060201

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077019974

Country of ref document: KR